BioCentury
ARTICLE | Company News

Confluence Pharmaceuticals, AOP Orphan deal

April 27, 2015 7:00 AM UTC

Confluence and AOP partnered to co-develop and market Confluence’s preclinical compound based on a formulation of acamproate, for pediatric Fragile X syndrome in the EU and Middle East. Confluence wil...